Opexa Therapeutics (OPXA) Earns Daily News Sentiment Rating of 0.12

Headlines about Opexa Therapeutics (NASDAQ:OPXA) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Opexa Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Separately, Zacks Investment Research upgraded Opexa Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, April 5th.

Opexa Therapeutics (NASDAQ:OPXA) opened at 0.89 on Friday. The firm has a 50-day moving average price of $0.76 and a 200 day moving average price of $0.80. Opexa Therapeutics has a one year low of $0.50 and a one year high of $4.93. The firm’s market capitalization is $6.81 million.

Opexa Therapeutics (NASDAQ:OPXA) last posted its quarterly earnings data on Friday, May 12th. The biopharmaceutical company reported ($0.12) EPS for the quarter. Opexa Therapeutics had a negative return on equity of 150.46% and a negative net margin of 274.79%. Equities research analysts anticipate that Opexa Therapeutics will post ($0.47) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Opexa Therapeutics (OPXA) Earns Daily News Sentiment Rating of 0.12” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/07/30/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-opexa-therapeutics-opxa-share-price-updated-updated-updated.html.

About Opexa Therapeutics

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:OPXA)

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply